Bisphosphonates: Mechanisms of action

Endocrine Reviews

Volumn 19, Issue 1, 1998, Pages 80-100

  Fleisch, Herbert ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; EB 1053; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; [1 HYDROXY 2 (IMIDAZO[1,2 A]PYRIDIN 3 YL)ETHYLIDENE]BISPHOSPHONIC ACID;

ALBERS SCHOENBERG DISEASE; BONE DEFECT; BONE DISEASE; BONE TUMOR; CALCIFICATION; CARTILAGE DEGENERATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TISSUE LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032468984     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.19.1.0325     Document Type: Review

References (274)

1. Menschutkin N 1865 Ueber die Einwirkung des Chloracetyls auf phosphorige Säure. Ann Chem Pharm 133:317-320
2. Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD 1969 Diphosphonates in the treatment of myositis ossificans. Lancet 2:845
3. Von Baeyer H, Hofmann KA 1897 Acetodiphosphorige Säure. Beitr Dtsch Chem Ges 30:1973-1978
4. Blomen LJMJ 1995 History of the bisphosphonates: discovery and history of the non-medical uses of bisphosphonates. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds) Bisphosponate on Bones. Elsevier, Amsterdam, pp 111-124
5. Fleisch H, Russell RGG, Bisaz S, Casey PA, Mühlbauer RC 1968 The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 2:10-10A
6. Fleisch H, Bisaz S 1962 Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203:671-675
7. Fleisch H, Russell RGG, Straumann F 1966 Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212:901-903
8. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA (eds) Bone and Mineral Research. Elsevier, Amsterdam, vol 8: 265-306
9. Sietsema WK, Ebetino FH 1994 Bisphosphonates in development for metabolic bone disease. Exp Opin Invest Drugs 3:1255-1276
10. Felix R 1995 Studies with isolated cells and cell systems. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds) Bisphosphonate on Bones. Elsevier, Amsterdam, pp 189-204
11. Mühlbauer RC 1995 Mechanisms of action of bisphosphonates: information from animal models. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds) Bisphosphonate on Bones. Elsevier, Amsterdam, pp 171-187
12. Fleisch H 1996 Bisphosphonates: mechanisms of action and clinical use. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of Bone Biology. Academic Press, San Diego, pp 1037-1052
13. Rodan GA, Fleisch H 1996 Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696
14. Fleisch H 1997 Bisphosphonates in bone disease. From the Laboratory to the Patient, ed 3. The Parthenon Publishing Group, New York
15. Fleisch H, Russell RGG, Bisaz S, Mühlbauer RC, Williams DA 1970 The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1:12-18
16. Rosenblum IY, Black HE, Ferrell JF 1977 The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcif Tissue Res 23:151-159
17. 2 MBP) on the development of ath-erosclerosis in the cynomolgus monkey. Atherosclerosis 31:307-325
18. Kramsch DM, Chan CT 1978 The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 42:562-571
19. Levy RJ, Schoen FJ, Lund SA, Smith MS 1987 Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. J Thorac Cardiovasc Surg 94:551-557
20. Levy RJ, Wolfrum J, Schoen FJ, Hawley MA, Lund SA, Langer R 1985 Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science 228:190-192
21. Golomb G, Langer R, Schoen FJ, Smith MS, Choi YM, Levy RJ 1986 Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: dose-response and mechanistic studies. J Contr Rel 4:181-194
22. Webb CL, Benedict JJ, Schoen FJ, Linden JA, Levy RJ 1987 Inhibition of bioprosthetic heart valve calcification with covalently bound aminopropanehydroxydiphosphonate. ASAIO Trans 33:592-595
23. Fraser D, Russell RGG, Pohler O, Robertson WG, Fleisch H 1972 The influence of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the development of experimentally induced urinary stones in rats. Clin Sci 42:197-207
24. Briner WW, Francis MD, Widder JS 1971 The control of dental calculus in experimental animals. Int Dent J 21:61-73
25. Plasmans CMT, Kuypers W, Slooff TJJH 1978 The effect of ethane-1-hydroxy-1,1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop 132:233-243
26. Ahrengart L, Lindgren U 1986 Prevention of ectopic bone formation by local application of ethane-1-hydroxy-1,1-diphosphonate (EHDP): an experimental study in rabbits. J Orthop Res 4:18-26
27. Fleisch H 1988 Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Baker PF (ed) Handbook of Experimental Pharmacology. Springer-Verlag, New York, vol 83: 440-466
28. Baumann JM, Bisaz S, Fleisch H, Wacker M 1978 Biochemical and clinical effects of ethane-1-hydroxy-1,1-diphosphonate in calcium nephrolithiasis. Clin Sci Mol Med 54:509-516
29. Mühlemann HR, Bowles D, Schatt A, Bernimoulin JP 1970 Effect of diphosphonate on human supragingival calculus. Helv Odont Acta 14:31-33
30. Sturzenberger OP, Swancar JR, Reiter G 1971 Reduction of dental calculus in humans through the use of a dentifrice containing a crystal-growth inhibitor. J Periodontol 42:416-419
31. Reiner M, Sautter V, Olah A, Bossi E, Largiadèr U, Fleisch H 1980 Diphosphonate treatment in myositis ossificans progressiva. In: Caniggia A (ed) Etidronate. Istituto Gentili, Pisa, pp 237-241
32. Slooff TJJH, Feith R, Bijvoet OLM, Nollen AJG 1974 The use of a diphosphonate in para-articular ossifications after total hip replacement. A clinical study. Acta Orthop Belg 40:820-828
33. Finerman GAM, Stover SL 1981 Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis Relat Res 4:337-342
34. Thomas BJ, Amstutz HC 1985 Results of the administration of diphosphonate for the prevention of heterotopic ossification after total hip arthoplasty. J Bone Joint Surg [Am] 67:400-403
35. King WR, Francis MD, Michael WR 1971 Effect of disodium ethane-1-hydroxy-1,1-diphosphonate on bone formation. Clin Orthop 78:251-270
36. 2 [scap]mDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196-214
37. Flora L, Hassing GS, Parfitt AM, Villanueva AR 1980 Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Rel Res 2:389-407
38. Larsson A 1974 The short-term effects of high doses of ethylene-1-hydroxy-1,1-diphosphonates upon early dentin formation. Calcif Tissue Res 16:109-127
39. Ogawa Y 1980 Disturbances in enamel and dentin formation of rat incisor following injection with sodium fluoride, strontium (II) chloride and EHDP. Jpn J Oral Biol 22:199-226
40. Weile V, Josephsen K, Fejerskov O 1990 Effects of single doses of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) on the mineralizing front of rat incisor enamel: a microradiographic and scanning electron microscopic study. Arch Oral Biol 35:857-867
41. Alatli I, Hammarström L 1996 Root surface defects in rat molar induced by 1-hydroxyethylidene-1,1-bisphosphonate. Acta Odontol Scand 54:59-65
42. Lenehan TM, Balligand M, Nunamaker DM, Wood Jr FE 1985 Effect of EHDP on fracture healing in dogs. J Orthop Res 3:499-507
43. Atkin I, Ornoy A, Pita JC, Muniz OE, Agundez A, Castiglione G, Howell DS 1988 EHDP-induced rachitic syndrome in rats is not reversed by vitamin D metabolites. Anat Rec 220:22-30
44. Hill LF, Lumb GA, Mawer EB, Stanbury SW 1973 Indirect inhibition of the biosynthesis of 1,25-dihydroxycholecalciferol in rats treated with a diphosphonate. Clin Sci 44:335-347
45. Baxter LA, DeLuca HF, Bonjour JP, Fleisch H 1974 Inhibition of vitamin D metabolism by ethane-1-hydroxy-1,1-diphosphonate. Arch Biochem Biophys 164:655-662
46. Bonjour JP, Russell RGG, Morgan DB, Fleisch H 1973 Intestinal calcium absorption, Ca-binding protein, and CA-ATPase in diphosphonate-treated rats. Am J Physiol 224:1011-1017
47. Trechsel U, Schenk R, Bonjour JP, Russell RGG, Fleisch H 1977 Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats. Am J Physiol 232:E298-E305
48. Guilland D, Trechsel U, Bonjour JP, Fleisch H 1975 Stimulation of calcium absorption and apparent increased intestinal, 1,25-dihydroxycholecalciferol in rats treated with low doses of ethane-1-hydroxy-1,1-diphosphonate. Clin Sci Mol Med 48:157-160
49. Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P 1971 The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate. J Lab Clin Med 78:574-584
50. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT 1984 Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1:821-824
51. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF 1993 Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460
52. Liens D, Delmas PD, Meunier PJ 1994 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343: 953-954
53. Reynolds JJ, Murphy H, Mühlbauer RC, Morgan DB, Fleisch H 1973 Inhibition by diphosphonates of bone resorption in mice and comparison with grey lethal osteopetrosis. Calcif Tissue Res 12: 59-71
54. Schenk R, Eggli P, Fleisch H, Rosini S 1986 Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349
55. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ 1972 The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43:31-45
56. 45Ca kinetics in the intact rat. Osteoporos Int 6:166-170
57. Mühlbauer RC, Fleisch H 1990 A method for continual monitoring of bone resorption in rats: evidence for a diurnal rhythm. Am J Physiol 259:R679-R689
58. Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, van der Wee-Pals LJA 1980 Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 32:145-157
59. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
60. Fleisch H, Russell RGG, Francis MD 1969 Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264
61. Russell RGG, Mühlbauer RC, Bisaz S, Williams DA, Fleisch H 1970 The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6:183-196
62. Trechsel U, Stutzer A, Fleisch H 1987 Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. A new model to study bone resorption in vivo. J Clin Invest 80:1679-1686
63. Mühlbauer RC, Russell RGG, Williams DA, Fleisch H 1971 The effects of diphosphonates, polyphosphates and calcitonin on "immobilisation osteoporosis" in rats. Eur J Clin Invest 1:336-344
64. Wronski TJ, Dann LM, Scott KS, Crooke LR 1989 Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats. Endocrinology 125:810-816
65. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 2577-2586
66. Wink CS, Onge MS, Parker B 1985 The effects of dichloromethylene bisphosphonate on osteoporotic femora of adult castrate male rats. Acta Anat (Basel) 124:117-121
67. 2 MBP. Calcif Tissue Int 47:169-172
68. Jee WSS, Black HE, Gotcher JE 1981 Effect of dichloromethane diphosphonate on cortisol-induced bone loss in young adult rabbits. Clin Orthop 156:39-51
69. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Ligata AA, Ross P, Woodson III GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut III CH 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
70. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut III CH 1993 Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567
71. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J 1994 Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595-1599
72. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs Jr RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 333:1437-1443
73. Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, Boldrini S, Troiani S, Massoni C 1996 Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 18:179-184
74. Ravn P, Clemmesen B, Riis BJ, Christiansen C 1996 The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19:527-533
75. Reid IR, King AR, Alexander CJ, Ibbertson HK 1988 Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143-146
76. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P 1989 Prevention of postmenopausal bone loss by tiludronate. Lancet 2:1469-1471
77. Hosking DJ, McClung MR, Ravn P, Wasnich RD, Thompson DE, Daley MS, Yates AJ 1996 Alendronate in the prevention of osteoporosis: EPIC study two-year results. J Bone Miner Res 11:S133
78. Forwood MR, Burr DB, Takano Y, Eastman DF, Smith PN, Schwardt JD 1995 Risedronate treatment does not increase micro-damage in the canine femoral neck. Bone 16:643-650
79. Toolan BC, Shea M, Myers ER, Borchers RE, Seedor JG, Quartuccio H, Rodan G, Hayes WC 1992 Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 7:1399-1406
80. Ammann P, Rizzoli R, Caverzasio J, Shigematsu T, Slosman D, Bonjour JP 1993 Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. J Bone Miner Res 8:1491-1498
81. Ferretti JL, Delgado CJ, Capozza RF, Cointry G, Montuori E, Roldán E, Pérez Lloret A, Zanchetta JR 1993 Protective effects of disodium etidronate and pamidronate against the biochemical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner 20:265-276
82. Motoie H, Nakamura T, O'Uchi N, Nishikawa H, Kanoh H, Abe T, Kawashima H 1995 Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovari-ectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 10:910-920
83. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of the effect of alendronate on the risk of fracture in women with existing vertebral fractures. Lancet 438:1535-1541
84. Galasko CSB, Samuel AW, Rushton S, Lacey E 1980 The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis. Br J Surg 67:493-496
85. Jung A, Mermillod B, Barras C, Baud M, Courvoisier B 1981 Inhibition by two diphosphonates of bone lysis in tumor conditioned media. Cancer Res 41:3233-3237
86. Johnson KY, Wesseler MA, Olson HM, Martodam RR, Poser JW 1982 The effects of diphosphonates on tumor-induced hypercalcemia and osteolysis in Walker carcinosarcoma 256 (W-256) of rats. In: Donath A, Courvoisier B (eds) Diphosphonates and Bone. Editions Médecine et Hygiène, Geneva, pp 386-389
87. Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ 1984 Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res 44:3007-3011
88. Martodam RR, Thornton KS, Sica DA, D'Souza SM, Flora L, Mundy GR 1983 The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int 35:512-519
89. Rizzoli R, Caverzasio J, Fleisch H, Bonjour JP 1986 Parathyroid hormone-like changes in renal calcium and phosphate reabsorption induced by Leydig cell tumor in thyroparathyroidectomized rats. Endocrinology 119:1004-1009
90. Fleisch H 1991 Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944
91. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice Cancer Res 55:3551-3557
92. Kostenuik PJ, Orr FW, Suyama K, Singh G 1993 Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 53:5452-5457
93. Mundy GR, Yoneda T 1995 Facilitation and suppression of bone metastasis. Clin Orthop 312:34-44
94. Jung A 1982 Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 72:221-226
95. Dunn CJ, Fitton A, Sorkin EM 1994 Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 5:446-474
96. Plosker GL, Goa KL 1994 Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47:945-982
97. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493
98. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
99. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D 1996 Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276
100. Gotcher JE, Jee WSS 1981 The progress of the periodontal syndrome in the rice rat II. The effects of a diphosphonate on the periodontium. J Periodont Res 16:441-455
101. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R 1992 Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 63:825-830
102. Shoji K, Horiuchi H, Shinoda H 1995 Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res 30:277-284
103. Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleisch H 1972 The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res 10:302-313
104. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39
105. Green JR, Müller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751
106. 2 MBP-coated bone. Bone Miner 6:33-43
107. Sato M, Grasser W 1990 Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40
108. Piper K, Boyde A, Jones SJ 1994 The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int 54:56-61
109. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011
110. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P 1983 Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99
111. Bijvoet OLM, Frijlink WB, Jie K, van der Linden H, Meijer CJLM, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP 1980 APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23:1193-1204
112. Boonekamp PM, Löwik CWGM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Bijvoet OLM 1987 Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 2:29-42
113. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991 BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011
114. Takeuchi M, Sakamoto S, Yoshida M, Abe T, Isomura Y 1993 Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylenebisphosphonate derivatives. Chem Pharm Bull (Tokyo) 41:688-693
115. Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G 1995 Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511-520
116. Storm T, Steiniche T, Thamsborg G, Melsen F 1993 Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199-208
117. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF 1995 The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10:211-221
118. Nii A, Fujimoto R, Okazaki A, Narita K, Miki H 1994 Intramembranous and endochondral bone changes induced by a new bisphosphonate (YM175) in the beagle dog. Toxicol Pathol 22:536-544
119. Tsuchimoto M, Azuma Y, Higuchi O, Sugimoto I, Hirata N, Kiyoki M, Yamamoto I 1994 Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 66:25-33
120. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A 1996 Human protein tyrosine phosphatase-σ alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 11:535-543
121. Fast DK, Felix R, Dowse C, Neuman WF, Fleisch H 1978 The effects of diphosphonates on the growth and glycolysis of connec-tive-tissue cells in culture. Biochem J 172:97-107
122. Guenther HL, Guenther HE, Fleisch H 1981 The effects of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells. Biochem J 196:293-301
123. Guenther HL, Guenther HE, Fleisch H 1981 The influence of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen. Biochem J 196:303-310
124. Guenther HL, Guenther HE, Fleisch H 1979 Effects of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on rabbit articular chondrocytes in culture. Biochem J 184: 203-214
125. Gallagher JA, Guenther HL, Fleisch H 1982 Rapid intracellular degradation of newly synthesized collagen by bone cells. Effect of dichloromethylenebisphosphonate. Biochim Biophys Acta 719:349-355
126. Giuliani N, Girasole G, Pedrazzoni M, Passeri G, Gatti C, Passeri M 1995 Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10:S171 (Abstract 129)
127. Ciosek CP, Magnin DR, Harrity TW, Logan JVH, Dickson JK, Gordon EM, Hamilton KA, Jolibois KG Kunselman LK, Lawrence RM, Mookhtiar KA, Rich LC, Slusarchyk DA, Sulsky RB, Biller SA 1993 Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268:24832-24837
128. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM 1987 Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301-1305
129. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL 1994 Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 4:320-322
130. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 355:1016-1021
131. Van Beek E, Hoekstra M, van de Ruit M, Löwik C, Papapoulos S 1994 Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875-1882
132. Plasmans CMT, Jap PHK, Kuijpers W, Slooff TJJH 1980 Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int 32:247-256
133. Francis MD 1969 The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 3:151-162
134. Francis MD, Russell RGG, Fleisch H 1969 Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264-1266
135. Hansen NM, Felix R, Bisaz S, Fleisch H 1976 Aggregation of hydroxyapatite crystals. Biochim Biophys Acta 451:549-559
136. Evans JR, Robertson WG, Morgan DB, Fleisch H 1980 Effects of pyrophosphate and diphosphates on the dissolution of hydroxyapatites using a flow system. Calcif Tissue Int 31:153-159
137. Jung A, Bisaz S, Fleisch H 1973 The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269-280
138. 2O; implications for polynuclear complex formation. J Phys Chem 76:1304-1310
139. Barnett BL, Strickland LC 1979 Structure of disodium dihydrogen 1-hydroxyethylidene-diphosphonate tetrahydrate: a bone growth regulator. Acta Crystallogr B 35:1212-1214
140. Meyer JL, Lee KE, Bergert JH 1977 The inhibition of calcium oxalate crystal growth by multidentate organic phosphonates. Calcif Tissue Res 28:83-86
141. Robertson WG, Peacock M, Nordin BEC 1973 Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43:31-37
142. Larsson SE 1976 The metabolic heterogeneity of glycosaminoglycans of the different zones of the epiphyseal growth plate and the effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) upon glycosaminoglycan synthesis in vivo. Calcif Tissue Res 21:67-82
143. Howell DS, Muniz OE, Blanco LN, Pita JC 1980 A micropuncture study of growth cartilage in phosphonate (EHDP) induced rickets. Calcif Tissue Int 30:35-42
144. Van den Bos T, Beertsen W 1987 Effects of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) on the synthesis of dentine matrix proteins in the mouse. Collagen Rel Res 7:135-147
145. Ogawa Y, Adachi Y, Hong S, Yagi T 1989 1-hydroxyethylidene-1,1-bisphosphonate (HEPB) simultaneously induces two distinct types of hypomineralization in the rat incisor dentine. Calcif Tissue Int 44:46-60
146. 2MBP) on the structure of the organic matrix of heterotopically induced bone tissue. Histochemistry 88:207-212
147. Palmoski M, Brandt K 1978 Effects of diphosphonates on glycosaminoglycan synthesis and proteoglycan aggregation in normal adult articular cartilage. Arthritis Rheum 21:942-949
148. Parfitt AM 1992 The physiologic and pathogenetic significance of bone histomorphometric data. In: Coe FL, Favus MJ (eds) Disorders of Bone and Mineral Metabolism. Raven Press, New York, pp 475-489
149. Eriksen EF, Vesterby A, Kassem M, Melsen F, Mosekilde L 1993 Bone remodeling and bone structure. In: Mundy GR, Martin TJ (eds) Physiology and Pharmacology of Bone. Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, vol 107:67-109
150. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF 1996 A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150-159
151. Boyce RW, Wronski TJ, Ebert DC, Stevens ML, Paddock CL, Youngs TA, Gundersen HJG 1995 Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone 16: 209-213
152. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G 1993 Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141
153. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MHL 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
154. Li M, Mosekilde Li Sogaard CH, Thomsen JS, Wronski TJ 1995 Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16:629-635
155. Jee WSS, Lin BY, Ma YF, Ke HZ 1995 Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats. J Bone Miner Res 10:963-970
156. Cheng PT, Chan C, Müller K 1995 Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate. J Bone Miner Res 10:119-126
157. Ma Y, Jee WSS, Chen Y, Gasser J, Ke HZ, Li XJ, Kimmel DB 1995 Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. J Bone Miner Res 10: 1726-1734
158. Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE 1996 Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats. J Bone Miner Res 11:169-177
159. Wimalawansa SJ 1995 Combined Therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 99:36-42
160. Hughes DE, MacDonald BR, Russell RGG, Gowen M 1989 Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930-1935
161. Cecchini MG, Felix R, Fleisch H, Cooper PH 1987 Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 2:135-142
162. Cecchini MG, Fleisch H 1990 Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5:1019-1027
163. Löwik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groot H, Bijvoet OLM 1988 Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 3:185-192
164. Vitté C, Fleisch H, Guenther HL 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-2333
165. Colucci S, Minielli V, Zambonin G, Grano M 1995 Etidronate inhibits osteoclast adhesion to bone surfaces but does not interfere with their specific recognition of single bone proteins. Ital J Miner Electrolyte Metab 9:159-164
166. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S 1996 Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705
167. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
168. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RGG 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11:1482-1491
169. Miller SC, Jee WSS 1979 The effect of dichloromethylenediphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec 193:439-462
170. Endo Y, Nakamura M, Kikuchi T, Shinoda H, Takeda Y, Nitta Y, Kumagai K 1993 Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 52:248-254
171. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T 1995 A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-144
172. Selander K, Lehenkari P, Väänänen HK 1994 The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 55:368-375
173. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
174. 14C] dichloromethylenebisphosphonate and [14C] 1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 36:108-113
175. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M 1995 Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-245
176. 2 [scap]mDP) and calcitonin on bone resorption, lactate production and phosphatase and pyrophosphatase content of mouse calvaria treated with parathyroid hormone in vitro. Calcif Tissue Res 13:287-294
177. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC 1990 Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456-461
178. Zimolo Z, Wesolowski G, Rodan GA 1995 Acid extrusion is induced by osteoclast attachment to bone: inhibition by alendronate and calcitonin. J Clin Invest 96:2277-2283
179. + -ATPase. J Bone Miner Res 11:1498-1507
180. Ende JJ 1979 Effects of Some Diphosphonates on the Metabolism of Bone in Vivo and in Vitro. PhD. Thesis, University of Leiden, Leiden, The Netherlands
181. Felix R, Russell RGG, Fleisch H 1976 The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 429:429-438
182. Delaissé JM, Eeckhout Y, Vaes G 1985 Bisphosphonates and bone resorption: effects on collagenase and lysosomal enzyme excretion. Life Sci 37:2291-2296
183. Felix R, Bettex JD, Fleisch H 1981 Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 33:549-552
184. Ohya K, Yamada S, Felix R, Fleisch H 1985 Effect of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria in culture. Clin Sci 69:403-411
185. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649
186. Felix R, Fleisch H 1975 Properties of inorganic pyrophosphatase of pig scapula cartilage. Biochem J 147:111-118
187. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA 1996 Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci USA 93:3068-3073
188. Deleted in proof
189. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ 1977 Clodronate and liposome-encapsulated clodronate are metabolised to a toxic ATP analogue, adenosine 5′(β,γ-dichloromethylene)triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367
190. Rodan GA, Martin TJ 1981 Role of osteoblasts in hormonal control of bone resorption: a hypothesis. Calcif Tissue Int 33:349-351
191. McSheehy PMJ, Chambers TJ 1986 Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption. Endocrinology 119:1654-1659
192. Perry HM, Skogen W, Chappel J, Kahn AJ, Wilner G, Teitelbaum SL 1989 Partial characterization of a parathyroid hormone-stimulated resorption factor(s) from osteoblast-like cells. Endocrinology 125:2075-2082
193. Morris CA, Mitnick ME, Weir EC, Horowitz H, Kreider BL, Isogna KL 1990 The parathyroid hormone-related protein stimulates human osteoblast-like cells to secrete a 9,000 Dalton bone resorbing protein. Endocrinology 126:1783-1785
194. 3. Endocrinology 131:1181-1187
195. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF 1996 A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150-159
196. Ishii T, Saito T, Morimoto K, Takeuchi Y, Asano S, Kumegawa M, Ogata E, Matsumoto T 1993 Estrogen stimulates the elaboration of cell/matrix surface-associated inhibitory factor of osteoclastic bone resorption from osteoblastic cells. Biochem Biophys Res Commun 191:495-502
197. Yu X, Schøller J, Foged NT 1996 Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 19: 339-345
198. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, Yamamoto M, Nagata N 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9-14
199. Chambers TJ 1980 Diphosphonates inhibit bone resorption by macrophages in vitro. J Pathol 132:255-262
200. Stevenson PH, Stevenson JR 1986 Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 38:227-233
201. De Vries E, van der Weij JP, van der Veen CJP, van Paassen HC, Jager MJ, Sleeboom HP, Bijvoet OLM, Cats A 1982 In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 47:157-163
202. Zernov IN, Stefani DV, Vel'tishchev YE 1979 Assessment of the protective action of diphosphonate compounds against damage to T-lymphocytes by antilymphocytic serum. Bull Exp Biol Med 87: 253-254
203. Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V, Engleman EG 1995 Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 10:1719-1725
204. Mönkkönen J, Pennanen N, Lapinjoki S, Urtti A 1994 Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 54:229-234
205. Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J 1995 Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharmacol Res 12:916-922
206. Makkonen N, Hirvonen MR, Teräväinen T, Savolainen K, Mönkkönen J 1996 Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther 277:1097-1102
207. Komissarenko SV, Zhuravskii NI, Karlova NP, Gulyi MF 1977 Inhibition of hypersensitivity of delayed and immediate types in guinea pigs by methylenediphosphonic acid. Bull Exp Biol Med 84:1322-1323
208. 2 activity. Agents Actions 16:41-42
209. Milhaud G, Labat ML, Moricard Y 1983 (Dichloromethylene) diphosphonate-induced impairment of T-lymphocyte function. Proc Natl Acad Sci USA 80:4469-4473
210. Labat ML, Tzehoval E, Moricard Y, Feldman M, Milhaud G 1983 Lack of a T-cell dependent subpopulation of macrophages in (dichloromethylene) diphosphonate-treated mice. Biomed Pharmacother 37:270-276
211. 2 MDP) reduces natural killer (NK) cell activity in mice. Metab Bone Dis Rel Res 5:281-287
212. Van Rooijen N, van Nieuwmegen R 1984 Elimination of phagocytic cells in the spleen after intravenous injection of liposomeencapsulated dichloromethylene diphosphonate: an enzyme-histochemical study. Cell Tissue Res 238:355-358
213. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331
214. Lioté F, Boval-Boizard B, Fritz P, Kuntz D 1995 Lymphocyte subsets in pamidronate-induced lymphopenia. Br J Rheumatol 34: 993-995
215. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962
216. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiébaud D 1996 Interleukin-6 and tumor necrosis factor a levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 18:133-139
217. Francis MD, Flora L, King WR 1972 The effects of disodium ethane-1-hydroxy-1,1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tissue Res 9:109-121
218. Flora L 1979 Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22:340-346
219. Francis MD, Hovancik K, Boyce RW 1989 NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 11:239-252
220. Dunn CJ, Galinet LA, Wu H, Nugent RA, Schlachter ST, Staite ND, Aspar DG, Elliott GA, Essani NA, Rohloff NA Smith RJ 1993 Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 266:1691-1698
221. Österman T, Kippo K, Lauren L, Hannuniemi R, Sellman R 1995 Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 44:258-263
222. Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nürnberg E, Emmrich F 1995 Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38: 1777-1790
223. 2 MDP-liposomes. Rheumatol Int 13:221-228
224. Osterman T, Kippo K, Laurén L, Hannuniemi R, Sellman R 1994 Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14:139-147
225. Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmström T 1983 Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146-149
226. Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HIJ, Vermey P, Elte JWF, Neijt JP, Beex LVAM, Blijham G 1987 Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2:983-985
227. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
228. Felix R, Fleisch H 1981 Increase in fatty acid oxidation in calvaria cells cultured with diphosphonates. Biochem J 196:237-245
229. Felix R, Fast DK, Sallis JD, Fleisch H 1980 Effect of diphosphonates on glycogen content of rabbit ear cartilage cells in culture. Calcif Tissue Int 30:163-166
230. Felix R, Fleisch H 1979 Increase in alkaline phosphatase activity in calvaria cells cultured with diphosphonates. Biochem J 183:73-81
231. 3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro. Calcif Tissue Int 42:248-254
232. Pilczyk R, Sutcliffe H, Martin TJ 1972 Effects of pyrophosphate and diphosphonates on parathyroid hormone- and fluoride-stimulated adenylate cyclase activity. FEBS Lett 24:225-228
233. Gebauer U, Russell RGG, Touabi M, Fleisch H 1976 Effect of diphosphonates on adenosine 3′:5′ cyclic monophosphate in mouse calvaria after stimulation by parathyroid hormone in vitro. Clin Sci Mol Med 50:473-478
234. Evéquoz V, Trechsel U, Fleisch H 1985 Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes. Bone 6:439-444
235. Talanian RV, Brown NC, McKenna CE, Ye TG, Levy JN, Wright GE 1989 Carbonyldiphosphonate, a selective inhibitor of mammalian DNA polymerase. Biochemistry 28:8270-8274
236. Eubank WB, Reeves RE 1982 Analog inhibitors for the pyrophosphate-dependent phosphofructokinase of entamoeba histolytica and their effect on culture growth. J Parasitol 68:599-602
237. Guilland DF, Sallis JD, Fleisch H 1974 The effect of two diphosphonates on the handling of calcium by rat kidney mitochondria in vitro. Calcif Tissue Res 15:303-314
238. Guilland DF, Fleisch H 1974 The effect of in vivo treatment with EHDP and/or 1,25-DHCC on calcium uptake and release in isolated kidney mitochondria. Biochem Biophys Res Commun 61: 906-911
239. Paspaliaris V, Leaver DD 1990 The bisphosphonate, clodronate, inhibits calcium-induced contraction in vascular smooth muscle. Eur J Pharmacol 183:1257
240. Greif F, Anais D, Frei L, Arbeit L, Sorroff HS 1990 Blocking the calcium cascade in experimental acute renal failure. Isr J Med Sci 26:301-305
241. Rossier JR, Cox JA, Niesor EJ, Bentzen CL 1989 A new class of calcium entry blockers defined by 1,3-diphosphonates. J Biol Chem 264:16598-16607
242. 3-methylenetetraphosphate). Biochemistry 27:1897-1901
243. Rogers MJ, Russell RGG, Blackburn GM, Williamson MP, Watts DJ 1992 Metabolism of halogenated bisphosphonates by the cellular slime mold Dictyostelium discoideum. Biochem Biophys Res Commun 189:414-423
244. Rogers MJ, Watts DJ, Russell RGG, Ji X, Xiong X, Blackburn GM, Bayless AV, Ebetino FH 1994 Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res 9:1029-1039
245. Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RGG, Bayless AV, Ebetino FH 1995 Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 47:398-402
246. Boulenc X, Marti E, Joyeux H, Roques C, Berger Y, Fabre G 1993 Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochem Pharmacol 46:1591-1600
247. Janner M, Mühlbauer RC, Fleisch H 1991 Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int 49:280-283
248. Boulenc X, Roques C, Joyeux H, Berger Y, Fabre G 1995 Bisphosphonates increase tight junction permeability in the human intestinal epithelial (Caco-2) model. Int J Pharmacol 123:13-24
249. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG 1995 Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
250. Wiedmer WH, Zbinden AM, Trechsel U, Fleisch H 1983 Ultrafiltrability and Chromatographic properties of pyrophosphate, 1-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylenebisphosphonate in aqueous buffers and in human plasma. Calcif Tissue Int 35:397-400
251. Grabenstetter RJ, Cilley WA 1971 Polynuclear complex formation in solutions of calcium ion and ethane-1-hydroxy-1,1-diphosphonic acid. I. Complexometric and pH titrations. J Phys Chem 75:676-682
252. Lamson ML, Fox JL, Huguchi WI 1984 Calcium and 1-hydroxyethylidene-1,1-bisphosphonic acid: polynuclear complex formation in the physiological range of pH. Int J Pharm 21:143-154
253. Lamson ML, Fox JL, Higuchi WI 1985 Model selection for complex systems involving polynuclear species. Polyhedron 4:133-141
254. Lin JH, Chen I-W, DeLuna FA 1994 Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. Drug Metab Dispos 22:400-405
255. Lin JH, Chen IW, DeLuna FA, Hichens M 1993 Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther 267:670-675
256. Troehler U, Bonjour JP, Fleisch H 1975 Renal secretion of diphosphonates in rats. Kidney Int 8:6-13
257. Lin JH 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85
258. Bisaz S, Jung A, Fleisch H 1978 Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 54:265-272
259. Fitton A, McTavish D 1991 Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318
260. Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, Benedict JJ 1982 Clodronate kinetics and bioavailability. Clin Pharmacol Ther 31:402-410
261. Conrad KA, Lee SM 1981 Clodronate kinetics and dynamics. Clin Pharmacol Ther 30:114-120
262. 99mTc-labelled APD in the mouse. Calcif Tissue Int 43:125-127
263. 3H-etidronate in rat and mouse bones. Bone 19:281-290
264. Sturtz G, Couthon H, Fabulet O, Mian M, Rosini S 1993 Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma. Eur J Med Chem 28: 899-903
265. 14C-labeled ethylene-1-hydroxy-1,1-diphosphonate in normal and treated young rats. An autoradiographic and ultrastructural study. Toxicol Appl Pharmacol 52:391-399
266. Wingen F, Schmähl D 1985 Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. Arzneimittelforschung 35:1565-1571
267. Mönkkönen J 1988 A one year follow-up study of the distribution of 14C-clodronate in mice and rats. Pharmacol Toxicol 62:51-53
268. Mönkkönen J, Koponen HM, Ylitalo P 1990 Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 66:294-298
269. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F 1983 Renal failure associated with intravenous diphosphonates. Lancet 1:471
270. Kasting GB, Francis MD 1992 Retention of etidronate in human, dog, and rat. J Bone Miner Res 7:513-522
271. Alden CL, Parker RD, Eastman DF 1989 Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol Pathol 17:27-32
272. Cal JC, Daley-Yates PT 1990 Disposition and nephrotoxicity of 3-animo-1-hydroxypropylidene-1,1-bisphosphonate (APD) in rats and mice. Toxicology 65:179-197
273. Eguchi M, Yamaguchi T, Shiota E, Handa S 1982 Fault of ossification and calcification and angular deformities of long bone in th mouse fetuses caused by high doses of ethane-1-hydroxy-1,1-diphosphonate (EHDP) during pregnancy. Cong Anom 22:47-52
274. Van Breukelen FJM, Bijvoet OLM, Frijlink WB, Sleeboom HP, Mulder H, van Oosterom AT 1982 Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif Tissue Int 34:321-327